IL28B Polymorphisms in Interferon-Treated Patients with Chronic Hepatitis B - European Medical Journal

IL28B Polymorphisms in Interferon-Treated Patients with Chronic Hepatitis B

Download PDF
Mauro Vigano,1 Pietro Lampertico2

No potential conflict of interest.

EMJ Hepatol. ;1:52-56. DOI/10.33590/emjhepatol/10310268.
Chronic Hepatitis B, HBsAg Clearance, IL28B Polymorphism, Pegylated Interferon Alpha, rs12979860, rs8099917, Sustained Response

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


Pegylated interferon (Peg-IFN) may achieve a sustained off-treatment response in 20-30% of the patients with chronic hepatitis B (CHB). However, given the high cost of treatment, the frequent side effects, and the lack of effectiveness in a large proportion of patients, there have been attempts to identify the subjects who are most likely to benefit with such therapy. Response rates may be significantly increased by careful selection of patients based upon baseline serum alanine aminotransferase, HBV DNA levels, and viral genotype. Recently, genome-wide association studies identified polymorphisms of the interleukin 28B (IL28B) gene as a potent predictor of sustained viral response in chronic hepatitis C patients treated with Peg-IFN plus Ribavirin, encouraging similar studies in HBV. Overall, these studies failed to provide convincing evidences that IL28B genotype significantly impacts on response to Peg-IFN in chronic hepatitis B (CHB) patients, though these studies are very heterogeneous in terms of patient populations, methodology, baseline features, treatment regimens, duration of follow-up, and ethnicity, making new studies in larger cohorts very much needed.

Please view the full content in the pdf above.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally